Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Michele Iuliani

10PUBLICATIONS

22CO-AUTHORS

Gene and molecular therapyPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (10)

Sort by Publication Date:

|Aug 28, 2024

S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models.

F Pantano, S Simonetti, M Iuliani

|Jun 22, 2024

Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).

Michele Iuliani, Sonia Simonetti, Leonardo Cristofani

|Sep 23, 2022

Osteoblast Secretome Modulated by Abiraterone Treatment Affects Castration Resistant Prostate Cancer Cell Proliferation.

Michele Iuliani, Sonia Simonetti, Giulia Ribelli

|Sep 14, 2022

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma.

Sonia Simonetti, Michele Iuliani, Marco Stellato

|May 28, 2022

Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients.

Francesco Pantano, Francesca Zalfa, Michele Iuliani

|Mar 10, 2022

Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.

Michele Iuliani, Sonia Simonetti, Giulia Ribelli

Pageof 2

Frequent Collaborators

3 joint publications

Sonia Simonetti

2 joint publications

Andrea Napolitano

1 joint publications

M J Guillen

1 joint publications

L Nibid

1 joint publications

G Perrone

1 joint publications

Oronzo Brunetti

1 joint publications

Nicola Silvestris

1 joint publications

Elisabetta Rossi

1 joint publications

Antonella Facchinetti

1 joint publications

Alice Zoccoli

Frequent Collaborators

3 joint publications

Sonia Simonetti

2 joint publications

Andrea Napolitano

1 joint publications

M J Guillen

1 joint publications

L Nibid

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on : May 22, 2020

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on : Mar 06, 2018

See more related videos

Top Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on : Oct 27, 2014

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on : May 22, 2020

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on : Mar 06, 2018

See more related videos